X @Bloomberg

Market Dynamics - AstraZeneca investors opposed the potential merger proposal valued at $400 billion (四千亿美元) with Bristol-Myers Squibb Co [1] Industry Trends - Pharmaceutical sector stakeholders showed negative sentiment toward large-scale cross-company consolidation moves [1]